Drugmakers have cited a range of constitutional challenges in their broad fight to block the Medicare negotiation provisions of the Inflation Reduction Act, some of which “are weaker than others,” according to legal experts.
The new law requires drugmakers to participate in Medicare price negotiations, or else pay a steep…
Click here to view original post
